Hope for Kids with Hives: Dupixent Nears EU Nod for Young Children

PARIS, FRANCE – February 27, 2026 – A potential breakthrough is on the horizon for some of the youngest patients suffering from a debilitating skin condition. Pharmaceutical giants Sanofi and Regeneron announced today that their blockbuster drug, Dupixent, has received a positive recommendation from a key European regulatory committee for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11.

The opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) paves the way for what could be the first targeted therapy approved in the European Union for this specific pediatric population. The recommendation covers children whose condition is not adequately controlled by standard-of-care antihistamines. A final, legally binding decision from the European Commission is anticipated in the coming months.

Addressing a Critical Unmet Need

For thousands of children and their families across Europe, a diagnosis of chronic spontaneous urticaria means a relentless cycle of sudden, intensely itchy hives and swelling that can appear without warning and persist for weeks or months. This chronic inflammatory skin disease, driven in part by an underlying immune response known as type 2 inflammation, can profoundly disrupt daily life. The constant itch can interfere with sleep, school, and social activities, taking a significant emotional and physical toll on young patients.

Currently, the standard treatment begins with high-dose H1-antihistamines. However, a significant number of patients, including children, fail to find relief with this approach. For them, the options are limited and often involve off-label use of medications with less robust safety and efficacy data in young children. While the biologic Omalizumab is approved for CSU, its indication starts at age 12, leaving a critical treatment gap for the younger pediatric population.

If the European Commission follows the CHMP's recommendation, Dupixent (dupilumab) would become the first biologic medicine specifically indicated to fill this void. It offers a targeted approach for children who are naive to other biologic therapies and have found no respite from the persistent and distressing symptoms of CSU.

The Science Behind the Breakthrough

The positive opinion for Dupixent is not based on hope alone, but on rigorous clinical data from the LIBERTY-CUPID study program. This program included several Phase 3 trials, notably Studies A and C, and the CUPIDKids study, which collectively evaluated the drug's efficacy and safety in this vulnerable population.

Unlike broad immunosuppressants, Dupixent is a fully human monoclonal antibody with a highly specific mechanism. It works by inhibiting the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are central drivers of the type 2 inflammation underlying CSU and other allergic diseases. By blocking these pathways, the drug aims to quell the inflammatory cascade at its source, reducing hive activity and itch.

The clinical trial results presented to the agency were compelling. Data from the LIBERTY-CUPID studies showed that Dupixent, when added to standard-of-care antihistamines, led to statistically significant and clinically meaningful reductions in both itch severity and urticaria activity compared to placebo. In one key study, patients treated with the drug experienced a nearly nine-point reduction in their weekly itch severity score, a substantial improvement over the placebo group. Furthermore, the safety profile observed in the pediatric CSU studies was consistent with Dupixent's well-established profile across its many other approved indications in over 1.4 million patients globally.

Expanding a Pharmaceutical Juggernaut

The potential expansion into pediatric CSU is a significant strategic step for Dupixent, a drug that has already transformed the treatment landscape for multiple inflammatory diseases and become a cornerstone of Sanofi and Regeneron's portfolios. With global sales reaching approximately $18.5 billion in 2025, Dupixent is a certified blockbuster, and its continued growth hinges on expanding its reach into new indications and patient populations.

The drug is already approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis in various age groups around the world. This latest recommendation reinforces the drug's role as a versatile pipeline-in-a-product and strengthens its developers' dominance in the immunology market. Each new approval not only provides a new revenue stream but also solidifies the scientific narrative around the central role of IL-4 and IL-13 in a wide array of inflammatory conditions.

The financial implications are substantial for both partners. Under their global collaboration agreement, Sanofi and Regeneron share the profits from Dupixent, making its success a shared victory. Continued label expansion is crucial as the companies look to maximize the drug's value before it begins to face patent expirations in the early 2030s.

Navigating the Path to Patients

While the CHMP's positive opinion is a critical milestone, the journey is not yet complete. The final marketing authorization rests with the European Commission, which generally follows the committee's advice. Following that, Sanofi and Regeneron will navigate the complex pricing and reimbursement negotiations within each EU member state to ensure patient access.

Simultaneously, the companies are pursuing a similar approval in the United States, where a supplemental Biologics License Application is currently under review by the Food and Drug Administration (FDA), with a decision expected by April 2026. This parallel regulatory effort underscores a global strategy to establish Dupixent as the standard of care for type 2 inflammatory diseases across all ages.

The competitive landscape for CSU is also heating up, with novel oral treatments and other biologics in late-stage development. However, by targeting this young, underserved pediatric group, Dupixent could carve out a crucial first-mover advantage. For the children who have spent their early years battling relentless hives and itch, the potential arrival of a new, targeted, and effective treatment represents a long-awaited chance at a normal childhood.